Heartsciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
HeartSciences Inc. filed its annual report for fiscal year 2026, detailing its ongoing development of AI-ECG technology and a proposed merger with Fortitude.
NASDAQ
10-K: HeartSciences Faces Going Concern Doubts Amidst Increased Losses and Nasdaq Compliance Challenges
HeartSciences Inc. reported a significant increase in net losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, while actively pursuing FDA clearances for its AI-ECG devices and addressing Nasdaq listing requirements.
NASDAQ
10-K: Heart Test Laboratories Files 10-K, Outlines Path to FDA Approval for AI-Powered ECG Technology
Heart Test Laboratories' 10-K filing details its financial status, ongoing development of AI-ECG technology, and plans for FDA submissions.